Related Experiment Video
Updated: Apr 23, 2026
Modeling Primary Bone Tumors and Bone Metastasis with Solid Tumor Graft Implantation into Bone
Published on: September 9, 2020
NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use
Gwen McCaffrey1, Michelle L Thompson1, Lisa Majuta1
1Department of Pharmacology, University of Arizona College of Medicine, Tucson, Arizona.
Abstract:
Studies in animals and humans show that blockade of nerve growth factor (NGF) attenuates both malignant and nonmalignant skeletal pain. While reduction of pain is important, a largely unanswered question is what other benefits NGF blockade might confer in patients with bone cancer. Using a mouse graft model of bone sarcoma, we demonstrate that early treatment with an NGF antibody reduced tumor-induced bone destruction, delayed time to bone fracture, and increased the use of the tumor-bearing limb. Consistent with animal studies in osteoarthritis and head and neck cancer, early blockade of NGF reduced weight loss in mice with bone sarcoma. In terms of the extent and time course of pain relief, NGF blockade also reduced pain 40% to 70%, depending on the metric assessed. Importantly, this analgesic effect was maintained even in animals with late-stage disease. Our results suggest that NGF blockade immediately upon detection of tumor metastasis to bone may help preserve the integrity and use, delay the time to tumor-induced bone fracture, and maintain body weight.
Insights
Blocking nerve growth factor (NGF) in bone cancer models reduces pain and preserves bone integrity. Early NGF antibody treatment also improved limb use and prevented weight loss in mice with bone sarcoma.
Area of Science:
- Oncology
- Pain Management
- Skeletal Biology
Background:
- Nerve growth factor (NGF) blockade is known to alleviate skeletal pain in both malignant and nonmalignant conditions.
- The broader therapeutic benefits of NGF blockade in bone cancer patients remain largely unexplored.
Purpose of the Study:
- To investigate the effects of NGF blockade beyond pain relief in a preclinical model of bone sarcoma.
- To assess the impact of NGF antibody treatment on bone destruction, fracture risk, limb function, and body weight in mice with bone cancer.
Main Methods:
- A mouse graft model of bone sarcoma was utilized.
- Mice received early treatment with an NGF antibody.
Main Results:
- NGF blockade significantly reduced tumor-induced bone destruction and delayed the onset of bone fractures.
- Treatment increased the use of the tumor-bearing limb and mitigated weight loss, consistent with previous studies.
- Substantial pain relief (40-70%) was observed, with efficacy maintained even in late-stage disease.
Conclusions:
- Early NGF blockade demonstrates multifaceted therapeutic potential in bone cancer, extending beyond analgesia.
- This approach may preserve skeletal integrity, enhance limb function, and maintain body weight in patients with bone metastases.
- Targeting NGF upon detection of bone metastasis could be a valuable strategy for improving patient outcomes.
More Related Videos
10:32Author Spotlight: Simple Establishment of a Vascularized Osteogenic Bone Marrow Niche Using Pre-Cast Poly(Ethylene Glycol) (PEG) Hydrogels in an Imaging Microplate
Published on: May 19, 2023
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Related Concept Videos
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Bone Remodeling and Repair
01:40Bone Remodeling